Online English Summarizer tool, free and accurate!
Iron oxide nanoparticles (IONPs) have emerged as a promising alternative to con- ventional contrast agents (CAs) for magnetic resonance imaging (MRI).Here, the fundamental principles of MRI contrast agents are discussed, and the current status of MRI contrast agents is reviewed with a focus on the advantages and limitations of current T1 contrast agents and the potential of IONPs to serve as safe and improved alternative to gadolinium-based chelates.This review addresses key aspects in the development of IONPs for MRI applications, namely, synthesis of the inorganic core, functionalization processes to make IONPs biocom- patible and also to target them to specific tissues or cells, and finally in vivo studies in animal models, with special emphasis on tumor models.Thus, IONPs functionalized with epithelial growth factor receptor antibodies, short peptides, like RGD, or aptamers, among others, have been proposed for the diagnosis of various types of cancer, including breast, stomach, colon, kidney, liver or brain cancer.Furthermore, the ease of functionalization of their surfaces with different types of ligands (antibodies, peptides, sugars, etc.) opens up the pos- sibility of carrying out molecular MRI.Studies in developing IONPs as T1 contrast agents have generated promising results, but the complex, interrelated parameters influencing contrast enhancement make the development difficult, and IONPs suitable for T1 contrast enhancement have yet to make their way to clinical use.The past advances and current challenges in developing IONPs as a T1 contrast agent from a materials science perspective are presented, and how each of the key material properties and environment variables affects the performance of IONPs is assessed.They have been extensively investigated as CAs due to their high biocompatibility and excel- lent magnetic properties.Gadolinium-based chelates are a mainstay of contrast agents for magnetic resonance imaging (MRI) in the clinic.However, their toxicity elicits severe side effects and the Food and Drug Administration has issued many warnings about their potential retention in patients' bodies, which causes safety concerns.Iron oxide nanoparticles (IONPs) are a potentially attractive alternative, because of their nontoxic and biodegradable nature.
Iron oxide nanoparticles (IONPs) have emerged as a promising alternative to con- ventional contrast agents (CAs) for magnetic resonance imaging (MRI). They have been extensively investigated as CAs due to their high biocompatibility and excel- lent magnetic properties. Furthermore, the ease of functionalization of their surfaces with different types of ligands (antibodies, peptides, sugars, etc.) opens up the pos- sibility of carrying out molecular MRI. Thus, IONPs functionalized with epithelial growth factor receptor antibodies, short peptides, like RGD, or aptamers, among others, have been proposed for the diagnosis of various types of cancer, including breast, stomach, colon, kidney, liver or brain cancer. In addition to cancer diagnosis, different types of IONPs have been developed for other applications, such as the detection of brain inflammation or the early diagnosis of thrombosis. This review addresses key aspects in the development of IONPs for MRI applications, namely, synthesis of the inorganic core, functionalization processes to make IONPs biocom- patible and also to target them to specific tissues or cells, and finally in vivo studies in animal models, with special emphasis on tumor models.
Gadolinium-based chelates are a mainstay of contrast agents for magnetic resonance imaging (MRI) in the clinic. However, their toxicity elicits severe side effects and the Food and Drug Administration has issued many warnings about their potential retention in patients’ bodies, which causes safety concerns. Iron oxide nanoparticles (IONPs) are a potentially attractive alternative, because of their nontoxic and biodegradable nature. Studies
in developing IONPs as T1 contrast agents have generated promising
results, but the complex, interrelated parameters influencing contrast enhancement make the development difficult, and IONPs suitable for T1 contrast enhancement have yet to make their way to clinical use. Here, the fundamental principles of MRI contrast agents are discussed, and the current status of MRI contrast agents is reviewed with a focus on the advantages and limitations of current T1 contrast agents and the potential of IONPs to serve as safe and improved alternative to gadolinium-based chelates. The past advances and current challenges in developing IONPs as a T1 contrast agent from a materials science perspective are presented, and how each of the
key material properties and environment variables affects the performance of IONPs is assessed. Finally, some potential approaches to develop high- performance and clinically relevant T1 contrast agents are discussed.
Summarize English and Arabic text using the statistical algorithm and sorting sentences based on its importance
You can download the summary result with one of any available formats such as PDF,DOCX and TXT
ٌYou can share the summary link easily, we keep the summary on the website for future reference,except for private summaries.
We are working on adding new features to make summarization more easy and accurate
I think we might be a little bit uncertain on the potential complications from after the surgery, li...
لخص في نقاط طيب بسم الله الرحمن الرحيم والصلاه والسلام على اشرف الانبياء والمرسلين نبينا محمد وعل...
تتمثل أنجازات القسم في قيام الهيئة البحثية بالقسم بإجراء البحوث والدرسات والرسائل العلمية في مجال تش...
الجامعة الإسلامية أنا لا أحب أنْ أخدع نفسي عن نفسي، ولا أحب أنْ أخدع الناس عنها. أنا مسلمٌ قبل كل ش...
الحمد لله الملك المعبود، سبحانه ، لا أُحصي ثناءً عليه هو كما أثنى على نفسه.وأصلي وأسلم على سيدنا محم...
رد وزير الخارجية الإيراني عباس عراقجي، مساء الأربعاء، على التصريحات الأخيرة لمفوضة الأمن والخارجية ف...
إنجازات وحدة تعريف الكائنات الدقيقة والمقاومة الحيوية تُعَد وحدة تعريف الكائنات الدقيقة والمقاومة ال...
chief economic responsibility that a firm has is to its owners or investors. They want to earn a pro...
dresse mes sincères remerciements à ceux qui ont contribué àl'élaboration de ma mémoire. Je tiens à ...
في الولايات المتحدة، تخضع الرعاية خارج المنزل - مثل الرعاية البديلة، والبيوت الجماعية، ومرافق العلاج...
السلا السلام عليكم متابعين الكرام معكم السيد والنهاردة هبتدي معاكم كورس مهم جدا جدا وهو ال human re...
السريرة لو كُشِفَ للإنسان عن سريرة الإنسان لرأى منها ما يرى من غرائب هذا الكون وعجائبه، أَعْمَى أَدْ...